Skip to main content

Table 1 Comparison of characteristics before and after propensity score matching (PSM)

From: Efficacy of AS versus SOX regimen as first-line chemotherapy for gastric cancer patients with peritoneal metastasis: a real-world study

Variable Before PSM p-value After PSM p-value
AS (%) SOX (%) AS (%) SOX (%)
Gender    0.0098    1.0000
 Male 29 (46.8) 56 (69.1)   29 (53.7) 29 (53.7)  
 Female 33 (53.2) 25 (30.9)   25 (46.8) 25 (46.8)  
Age    0.3440    1.0000
  ≤ 65 48 (77.4) 56 (69.1)   43 (79.6) 43 (79.6)  
 > 65 14 (22.6) 25 (30.9)   11 (20.4) 11 (20.4)  
Ascites    0.2177    1.0000
 Without 26 (41.9) 25 (30.9)   21 (38.9) 20 (37.0)  
 With 36 (58.1) 56 (69.1)   33 (61.1%) 34 (63.0)  
Lauren type    0.0006    0.0172
 Intestinal 4 (6.5) 26 (32.1) 0.3169a 4 (7.4) 15 (27.8) 0.5255b
 Diffuse 42 (67.7) 35 (43.2)   34 (63.0) 24 (44.4)  
 Mixed 16 (25.8) 20 (24.7)   16 (29.6) 15 (27.8)  
Cycles    0.0290    0.2318
 ≤ 3 9 (14.5) 25 (30.9)   8 (14.8) 14 (25.9)  
 > 3 53 (85.5) 56 (69.1)   46 (85.2) 40 (74.1)  
Surgery    0.6602    1.0000
 Yes 5 (8.1) 5 (6.2)   5 (9.3) 5 (9.3)  
 No 57 (91.9) 76 (93.8)   49 (90.7) 49 (90.7)  
Inhibitor    0.4099    0.3750
 Yes 8 (12.9) 7 (8.6)   8 (14.8) 5 (9.3)  
 No 54 (87.1) 74 (91.4)   46 (85.2) 49 (90.7)  
HER2    0.7631    1.0000
 Negative 56 (90.3) 75 (92.6)   49 (90.7) 49 (90.7)  
 Positive 6 (9.7) 6 (7.4)   5 (9.3) 5 (9.3)  
Trastuzumabc    1.0000    1.0000
 No 1 (16.7) 1 (16.7)   1 (20) 1 (20)  
 Yes 5 (83.3) 5 (83.3)   4 (80) 4 (80)  
Total 62 (100) 81 (100)   54 (100) 54 (100)  
  1. ap-value between diffuse and mixed lauren type before PSM
  2. bp-value between diffuse and mixed lauren type after PSM
  3. ctrastuzumab in HER2 positive patients; Surgery, palliative surgery during or after first line chemotherapy; Inhibitor, checkpoint inhibitor